Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: John Pitera who wrote (45)	12/1/1999 2:58:00 PM
From: adad69	Read Replies (1) \| Respond to of 2850

The big player in this is TQNT

To: John Pitera who wrote (45)	12/1/1999 3:00:00 PM
From: wlheatmoon	Respond to of 2850

Wednesday December 1, 8:59 am Eastern Time Company Press Release SOURCE: Matritech, Inc. Matritech Issued Patent Extending U.S. Coverage of Its Fluid-Based Nuclear Matrix Protein Cancer Detection Technology Until 2011 NEWTON, Mass., Dec. 1 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS - news), a company specializing in products designed to detect, manage and screen cancer, announced today that it has been awarded U.S. Patent No. 5,989,826 for its proprietary fluid-based nuclear matrix protein (NMP) technology to detect cancer in body fluid samples including blood, urine, spinal fluid and sputum. The patent provides protection in the United States until 2011 for all of Matritech's fluid-based assays currently being sold or under development, including the NMP22© Bladder Cancer Test Kit, the NuMA(TM) Colon Cancer Test Kit, the breast and prostate cancer tests under development and future tests for other cancer types. ``The significance of this patent is that it extends protection for the clinical use of fluid-based nuclear matrix proteins for the detection and management of cancer patients until 2011,' said David L. Corbet, President and Chief Operating Officer of Matritech. ``This issuance is the twelfth U.S. patent Matritech has secured covering nuclear matrix protein technology, and strengthens our patent position in all NMPs for the detection and management of cancer. Matritech has additional applications pending with the U.S. Patent and Trademark Office for other NMP inventions.' Matritech's NMP core technology correlates levels of NMPs in body fluids to the presence of cancer. Multiple published clinical studies have validated this ability of NMPs to detect early-stage cancerous abnormalities. Matritech has a deep pipeline of NMP-based products in pre-clinical and clinical development for the detection of major cancers including bladder, cervical, colon, breast and prostate cancers. The NMP22 Test Kit is cleared for marketing in the United States for the management of patients with transitional cell carcinoma of the urinary tract. It is also sold in Europe and Japan, where it is the only approved kit for bladder cancer screening. Matritech, Inc., based in Newton, Mass., is using its proprietary nuclear matrix protein technology, discovered at the Massachusetts Institute of Technology and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast and prostate cancers. Statement Under the Private Securities Litigation Reform Act Any forward-looking statements related to the Company's expectations regarding the Company's existing and future projects are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include, but are not limited to, risks related to the Company's reliance on distribution partners, limited capital resources, unforeseen delays in product development or denials of FDA and other regulatory approvals, future product demand and pricing, competitive products and technical developments and general business and economic conditions. There can be no assurance that the Company's expectation for its products will be achieved. SOURCE: Matritech, Inc.

To: John Pitera who wrote (45)	12/12/1999 7:27:00 PM
From: John Pitera	Read Replies (2) \| Respond to of 2850

RFMD--Strives to be Dominant Player in Wireless Industry ( an update on RFMD on TSCN's Wallstreetcity.com,--- although RFMD has had very good revenue and sales growth, 73% of revenue this past year came from NOK. NEC, Phillips, and Siemens, have begun to develop and market their own GaAs HBT products. These large, established companies' entering this market will ultimately have a significant impact on prices for these products If NOK decided to go to one of the other vendors, RFMD would be affected in a pretty adverse way) (these have been my comments, article is below the line) (John) (for more RFMD background read the Post I responded too) ---------------------------------------------- Stocks in Focus Dec 10 1999 10:00AM CST Archives... RFMD Strives to be Dominant Player in Wireless Industry RF Micro Devices {RFMD} is an industry leader in custom designed radio frequency integrated circuits (RFICs). Incorporated in 1991, the Greensboro, North Carolina-based company designs, develops, manufactures and markets RFICs for various wireless applications such as cellular and personal communications services, cordless phones, wireless local area networks, wireless local loop handsets, industrial radios, wireless security systems and remote meter readers. The company strives to be the dominant supplier of RF products by offering a full range of standard and proprietary products including power amplifiers, modulators/demodulators, low noise amplifiers/mixers, transmitters, receivers and transceivers. They use three distinct process technologies to design their products - gallium arsenide heterojunction bipolar transistor, or GaAs HBT, silicon bipolar transistor, and gallium arsenide metal semiconductor field effect transistor, or GaAs MESFET. The explosive growth in wireless communications, specifically cellular and PCS phones, has helped drive the growth in the company's revenues from $45.3 million in March of 1998 to $152.1 million in March of 1999. Net income increased to $19.5 million in March of 1999 from a loss of $523,000 in March of 1998. EPS for FY 1999 were $0.26 versus a loss of $0.01 for FY 1998. Projected EPS for FY 2000 and 2001 are $0.59 and $0.78, respectively. Insiders own 37.0 percent of the 79 million shares outstanding and institutions own 67.9 percent, representing a float of 50.0 million shares. Historically, the semiconductor industry has been characterized by "feast or famine" cycles. In RFMD's case, this characteristic is compounded by the fact that merely two customers generate the majority of their revenue. For the fiscal year ending March 31, 1999, sales to Nokia totaled $112.2 million, or 73 percent of RFMD's revenue. Motorola ranks as RFMD's second largest customer. The company expects this trend to continue, stating in their latest annual report that for fiscal year 1999, their top five customers accounted for 87 percent of their total revenue, up from 70 percent in fiscal 1998. The company addresses this issue by stating that the manufacture of exclusive, complex custom products for individual customers along with capacity constraints makes it difficult to expand their customer base. Also, the company's GaAs HBT products generate a substantial portion of total revenues, representing 87 percent of FY 1999 revenue. The company also expects this situation to continue. This heavy reliance on revenues generated by a single technology looms as a potential problem because competitors, which include NEC, Phillips, and Siemens, have begun to develop and market their own GaAs HBT products. These large, established companies' entering this market will ultimately have a significant impact on prices for these products. RFMD will have to address several issues in order to continue its success in the wireless communications industry. Factors that will play important roles include maintaining their leading role in the development of quality proprietary products, implementing measures to diversify their customer base and maintaining sufficient manufacturing capacity to meet increasing customer demand for RFIC products. wallstreetcity.com